$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000162828020002424 Filed on February 27, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4
Revenue	$68.00K	$244.6K	$80.00K
YoY Change	9.64%	-35.34%	-56.76%
Cost Of Revenue		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit		$244.6K	$80.00K
YoY Change		-211.64%	-140.0%
Gross Profit Margin		100.0%	100.0%
Selling, General & Admin	$1.486M	$5.761M	$1.680M
YoY Change	8.06%	-28.04%	-9.19%
% of Gross Profit		2354.92%	2100.0%
Research & Development	$2.706M	$11.16M	$2.500M
YoY Change	2.17%	36.72%	103.25%
% of Gross Profit		4562.87%	3125.0%
Depreciation & Amortization	$119.0K	$494.2K	$160.0K
YoY Change	-6.14%	-42.5%	-44.83%
% of Gross Profit		202.03%	200.0%
Operating Expenses	$4.192M	$16.92M	$4.180M
YoY Change	4.18%	-2.92%	5.32%
Operating Profit	-$4.124M	-$16.68M	-$4.100M
YoY Change	4.1%	-2.2%	-1.66%
Interest Expense	$40.00K	$0.00	$110.0K
YoY Change		-100.0%	-92.03%
% of Operating Profit
Other Income/Expense, Net	-$3.000K	$0.00	-$170.0K
YoY Change	-249.25%	-100.0%	0.0%
Pretax Income	-$4.090M	-$16.41M	-$4.160M
YoY Change	4.87%	-0.3%	61.87%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.089M	-$16.41M	-$4.160M
YoY Change	4.72%	-0.29%	61.87%
Net Earnings / Revenue	-6013.24%	-6709.74%	-5200.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$412.7K	-$2.749M	-$1.081M
COMMON SHARES
Basic Shares Outstanding	10.21M shares	5.974M shares	22.99M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.300M	$10.20M	$11.50M
YoY Change	-17.7%	-11.3%	40.24%
Cash & Equivalents	$9.277M	$10.20M	$11.45M
Short-Term Investments
Other Short-Term Assets	$900.0K	$1.000M	$1.100M
YoY Change	0.0%	-9.09%	-8.33%
Inventory
Prepaid Expenses	$899.5K		$1.144M
Receivables	$106.4K	$200.0K	$167.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.28M	$11.40M	$12.77M
YoY Change	-16.65%	-10.94%	34.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$758.5K	$1.600M	$1.304M
YoY Change	158.56%	23.08%	-46.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$156.4K	$200.0K	$102.8K
YoY Change	79.58%	100.0%	-73.64%
Total Long-Term Assets	$1.532M	$1.700M	$1.407M
YoY Change	-30.24%	21.43%	-50.03%
TOTAL ASSETS
Total Short-Term Assets	$10.28M	$11.40M	$12.77M
Total Long-Term Assets	$1.532M	$1.700M	$1.407M
Total Assets	$11.82M	$13.10M	$14.17M
YoY Change	-18.7%	-7.75%	15.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$599.0K	$700.0K	$664.8K
YoY Change	28.33%	0.0%	-19.44%
Accrued Expenses	$3.412M	$3.700M	$1.772M
YoY Change	68.75%	164.29%	21.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.881M	$4.800M	$2.923M
YoY Change	48.61%	65.52%	-25.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$139.0K	$1.000M	$42.00K
YoY Change	-91.31%	-16.67%	-97.67%
Total Long-Term Liabilities	$139.0K	$1.000M	$42.00K
YoY Change	-91.31%	-16.67%	-97.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.881M	$4.800M	$2.923M
Total Long-Term Liabilities	$139.0K	$1.000M	$42.00K
Total Liabilities	$5.672M	$5.800M	$4.088M
YoY Change	17.02%	41.46%	-29.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$213.0M		-$192.2M
YoY Change	8.46%		11.06%
Common Stock	$8.554K		$7.742K
YoY Change	8.2%		46.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.141M	$7.300M	$10.08M
YoY Change
Total Liabilities & Shareholders Equity	$11.82M	$13.10M	$14.17M
YoY Change	-18.7%	-7.75%	15.36%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$4.089M	-$16.41M	-$4.160M
YoY Change	4.72%	-0.29%	61.87%
Depreciation, Depletion And Amortization	$119.0K	$494.2K	$160.0K
YoY Change	-6.14%	-42.5%	-44.83%
Cash From Operating Activities	-$3.374M	-$13.27M	-$3.610M
YoY Change	0.42%	0.52%	8.41%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$67.62K	$0.00
YoY Change	-100.0%	1225.92%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$0.00	-$67.62K	$0.00
YoY Change	-100.0%	-396.04%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.000M	$8.818M
YoY Change		-25.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.456M	$12.08M	0.000
YoY Change	-24.25%	-26.37%	-100.0%
NET CHANGE
Cash From Operating Activities	-$3.374M	-$13.27M	-3.610M
Cash From Investing Activities	$0.00	-$67.62K	0.000
Cash From Financing Activities	$2.456M	$12.08M	0.000
Net Change In Cash	-$918.0K	-$1.258M	-3.610M
YoY Change	646.01%	-138.97%	-568.83%
FREE CASH FLOW
Cash From Operating Activities	-$3.374M	-$13.27M	-$3.610M
Capital Expenditures	$0.00	$67.62K	$0.00
Free Cash Flow	-$3.374M	-$13.34M	-$3.610M
YoY Change	0.26%	0.99%	7.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10209587	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	13552560	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	trov	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	341015	USD
CY2019Q4	trov	Accrued Preferred Stock Dividend AccruedPreferredStockDividend	365255	USD
CY2018Q4	trov	Accrueddirectorfees Accrueddirectorfees	80008	USD
CY2019Q4	trov	Accrueddirectorfees Accrueddirectorfees	67500	USD
CY2018Q4	trov	Accruedresearchagreements Accruedresearchagreements	319898	USD
CY2019Q4	trov	Accruedresearchagreements Accruedresearchagreements	1686068	USD
CY2019	trov	Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock	0	USD
CY2018	trov	Beneficial Conversion Feature For Issuance Of Series B Convertible Preferred Stock BeneficialConversionFeatureForIssuanceOfSeriesBConvertiblePreferredStock	0	USD
CY2018	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	74518	shares
CY2019	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	497313	shares
CY2018	trov	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	48915	shares
CY2018	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	3450000	shares
CY2019	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	7437454	shares
CY2017Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	68.07
CY2018Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	8.91
CY2019Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	4.08
CY2018	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	21.60
CY2019	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	6.60
CY2018	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	217.17
CY2018	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	6.60
CY2019	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.87
CY2018	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	0	USD
CY2019	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	1675000	USD
CY2018Q4	trov	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	41041000	USD
CY2019Q4	trov	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	43821000	USD
CY2018Q4	trov	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3595000	USD
CY2019Q4	trov	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	3710000	USD
CY2019Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour	3423	USD
CY2019Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree	5868	USD
CY2019Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	676992	USD
CY2019Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths	574206	USD
CY2019	trov	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	76000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1771842	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3260061	USD
CY2019	trov	Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	235640	USD
CY2018	trov	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.03
CY2019	trov	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	-0.02
CY2018	trov	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	481000	USD
CY2019	trov	Income Tax Reconciliation Permanent Items IncomeTaxReconciliationPermanentItems	353000	USD
CY2018	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2019	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-776806	USD
CY2018	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	USD
CY2019	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-302491	USD
CY2019	trov	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2019Q4	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	1260489	USD
CY2019	trov	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2019	trov	Lessor Number Of Subleases LessorNumberOfSubleases	2
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Next Twelve Months OperatingLeasesFutureMinimumPaymentsDueNetNextTwelveMonths	581416	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Total OperatingLeasesFutureMinimumPaymentsDueNetTotal	2500542	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Netin Five Years OperatingLeasesFutureMinimumPaymentsDueNetinFiveYears	3423	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Netin Four Years OperatingLeasesFutureMinimumPaymentsDueNetinFourYears	5868	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Netin Three Years OperatingLeasesFutureMinimumPaymentsDueNetinThreeYears	968165	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Netin Two Years OperatingLeasesFutureMinimumPaymentsDueNetinTwoYears	941670	USD
CY2018Q4	trov	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	58398	USD
CY2019Q4	trov	Patentlicenseandotherfeespayable Patentlicenseandotherfeespayable	69950	USD
CY2018	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24240	USD
CY2019	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	24240	USD
CY2019Q4	trov	Related Party Committed Expenditures RelatedPartyCommittedExpenditures	1470000	USD
CY2019	trov	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	703327	USD
CY2018	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	0	USD
CY2019	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	703327	USD
CY2018	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-11779525	USD
CY2019	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-8817772	USD
CY2018Q4	trov	Servicereceivable Servicereceivable	0	USD
CY2019Q4	trov	Servicereceivable Servicereceivable	971673	USD
CY2019Q1	trov	Servicereceivable Servicereceivable	1675000	USD
CY2018	trov	Stock Issued During Period Restricted Stock Units StockIssuedDuringPeriodRestrictedStockUnits	18609	shares
CY2019	trov	Stock Issued During Period Restricted Stock Units StockIssuedDuringPeriodRestrictedStockUnits	22057	shares
CY2018	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1612667	USD
CY2019	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3299510	USD
CY2017	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P4Y4M21D
CY2018	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P4Y4M21D
CY2019	trov	Warrants Weighted Average Contractual Term WarrantsWeightedAverageContractualTerm	P3Y8M1D
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	664840	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	656304	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	107006	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	21000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2110061	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2604293	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	167755	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	203480	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202267605	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217172528	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2174627	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884942	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2174627	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884943	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3763695	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11617078	shares
CY2018Q4	us-gaap	Assets Assets	14172496	USD
CY2019Q4	us-gaap	Assets Assets	13086546	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	12765265	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	11353729	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11453133	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10195292	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8225764	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11453133	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195292	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3227369	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1257841	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	322774	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3649341	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10589482	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3831879	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8593633	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3831879	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8593633	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	7742	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	8312	USD
CY2019Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	333333	shares
CY2019Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	333333	shares
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	597457	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1307000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2634000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3735000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2782000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	166000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	486636	USD
CY2019Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1090671	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2428000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-148000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	41041000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	43987000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35019000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38494000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1126000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1252000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1301000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	531000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3734000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2781000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance Current DeferredTaxAssetsValuationAllowanceCurrent	41041000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance Current DeferredTaxAssetsValuationAllowanceCurrent	43821000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	154000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12000	USD
CY2018	us-gaap	Depreciation Depreciation	736088	USD
CY2019	us-gaap	Depreciation Depreciation	494232	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	859487	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	494232	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	32315	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4127	USD
CY2018	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-52000	USD
CY2018	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24240	USD
CY2019	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24240	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.26
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.75
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.40
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.05
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.17
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	875000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.00
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	780848	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1003383	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-362949	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17974	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	187500	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3734000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2780000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3457000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3447000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-184000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-177000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	574000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	384000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	214484	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1455336	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-19262	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35725	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-59206	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	23755	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54778	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	22000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	86368	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-21451	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-115459	USD
CY2018	us-gaap	Interest Expense InterestExpense	25409	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	22482	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	219430	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	234169	USD
CY2019	us-gaap	Lease Cost LeaseCost	63225	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1842835	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	865379	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3423	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5868	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	968165	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	116493	USD
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	582346	USD
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	291173	USD
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2019Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	291173	USD
CY2018Q4	us-gaap	Liabilities Liabilities	4088304	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5775202	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14172496	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13086546	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2923318	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4781744	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16403540	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12077281	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22842	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67622	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13199013	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13267500	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-16461178	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-16414159	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19254951	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16706668	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19254951	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16706668	USD
CY2018	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	109922	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Operating Expenses OperatingExpenses	17431737	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	16923126	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-17053412	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-16678494	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	444878	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1726342	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865379	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	860963	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	916762	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697418	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2833666	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	914540	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3423	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5868	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	968165	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	941670	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	0	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	84669	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46905	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102798	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157576	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	42000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	128368	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-236833	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1978	USD
CY2018	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	175381	USD
CY2019	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	31500	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5100	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67622	USD
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24240	USD
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	24240	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1144377	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	954957	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11779525	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8817772	USD
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	4386762	USD
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-40000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	31500	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	27942	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1612667	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3299509	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3414494	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3482116	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1304433	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	877823	USD
CY2018	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1200033	USD
CY2019	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8164011	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11162236	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	664686	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	187500	USD
CY2019	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192191215	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208897883	USD
CY2019	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
CY2018	us-gaap	Revenues Revenues	378325	USD
CY2019	us-gaap	Revenues Revenues	244632	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8005583	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5760890	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2174627	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	884943	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1864537	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	386654	USD
CY2019	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1994929	shares
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4386762	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-40000	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6506107	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10084192	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7311344	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	381653	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	617072	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	28188	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2330180	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5408124	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4750993	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6024680	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5180221	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5973906	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2330180	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5973906	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in fixed income instruments denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revision of Previously Issued Financial Statements for Correction of Immaterial Errors</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2019, the Company identified an immaterial error related to pre-funded warrants. The correction of the error resulted in higher weighted-average shares used to compute basic and diluted net loss per share for the three months ended June 30, 2019 and September 30, 2019, the six months ended June 30, 2019 and the nine months ended September 30, 2019. </font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-002424-index-headers.html	Edgar Link	pending
0001628280-20-002424-index.html	Edgar Link	pending
0001628280-20-002424.txt	Edgar Link	pending
0001628280-20-002424-xbrl.zip	Edgar Link	pending
exhibit231q42019.htm	Edgar Link	pending
exhibit311q42019.htm	Edgar Link	pending
exhibit312q42019.htm	Edgar Link	pending
exhibit321q42019.htm	Edgar Link	pending
exhibit322q42019.htm	Edgar Link	pending
exhibit416q42019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-123119x10k.htm	Edgar Link	pending
trov-20191231.xml	Edgar Link	completed
trov-20191231.xsd	Edgar Link	pending
trov-20191231_cal.xml	Edgar Link	unprocessable
trov-20191231_def.xml	Edgar Link	unprocessable
trov-20191231_lab.xml	Edgar Link	unprocessable
trov-20191231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2020 Q1 Form 10-K Financial Statement

#000162828020002424 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2020 Q1 Form 10-K Financial Statement

#000162828020002424 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf